Corcept Therapeutics (CORT) Receivables - Net (2012 - 2026)
Corcept Therapeutics (CORT) posted Receivables - Net of $76.9 million for Q2 2026, up 96.87% sequentially from $39.1 million in Q1 2026, and up 19.13% YoY from $64.6 million in Q2 2025.
Corcept Therapeutics (CORT) Receivables - Net (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Receivables - Net for 15 years, with the latest figure at $76.9 million in Q2 2026.
- Quarterly Receivables - Net rose 19.13% year-over-year to $76.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $76.9 million (up 19.13% YoY) and the FY2025 annual result came in at $59.8 million, up 10.76% from the prior year.
- Receivables - Net improved to $76.9 million in Q2 2026 per CORT's latest filing, from $39.1 million in the prior quarter.
- Over five years, Receivables - Net peaked at $76.9 million in Q2 2026 and troughed at $27.2 million in Q1 2022.
- A 5-year average of $47.6 million and a median of $47.5 million in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2024 and 2026: Receivables - Net jumped 88.95% in 2024, then sank 36.8% in 2026.
- Over 5 years, Receivables - Net stood at $31.1 million in 2022, then jumped by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then grew by 10.76% to $59.8 million in 2025, then grew by 28.66% to $76.9 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $76.9 million, $39.1 million, and $59.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.92 Mn |
| Jun 30, 2026 | 76.92 Mn |
| Mar 31, 2026 | 39.07 Mn |
| Mar 31, 2026 | 39.07 Mn |
| Dec 31, 2025 | 59.79 Mn |
| Dec 31, 2025 | 59.79 Mn |
| Sep 30, 2025 | 69.63 Mn |
| Sep 30, 2025 | 69.63 Mn |
| Jun 30, 2025 | 64.57 Mn |
| Jun 30, 2025 | 64.57 Mn |
| Mar 31, 2025 | 61.82 Mn |
| Mar 31, 2025 | 61.82 Mn |
| Dec 31, 2024 | 53.98 Mn |
| Dec 31, 2024 | 53.98 Mn |
| Sep 30, 2024 | 59.72 Mn |
| Sep 30, 2024 | 59.72 Mn |
| Jun 30, 2024 | 53.84 Mn |
| Jun 30, 2024 | 53.84 Mn |
| Mar 31, 2024 | 61.52 Mn |
| Mar 31, 2024 | 61.52 Mn |